GSK receives approval for ARNUITY™ ELLIPTA® (fluticasone furoate) in Canada for the treatment of asthma
MISSISSAUGA, ON, Sept. 29, 2015 /CNW/ - ARNUITY™ ELLIPTA® (fluticasone furoate dry powder for oral inhalation) has been approved in Canada as a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of steroid-responsive bronchial asthma in patients aged 12 years and older.
The approved strengths are ARNUITY™ ELLIPTA® 100 mcg and 200 mcg. ARNUITY™ is administered once daily via the dry powder inhaler called ELLIPTA®, which is also used across a range of other approved respiratory medicines in the GSK portfolio.
Sally Taylor, Country Medical Officer, Canada said: "ARNUITY™ ELLIPTA®, a GSK asthma treatment approved in Canada, provides physicians with a once-daily treatment option delivered via the ELLIPTA® inhaler to meet the needs of appropriate patients aged 12 and above."
Please consult the Product Monograph that will be posted at www.gsk.ca for complete safety information. The Product Monograph is also available by calling 1-800-387-7374.
ARNUITY and ELLIPTA are trademarks of Glaxo Group Limited, used under license by GlaxoSmithKline Inc.
About Asthma
Asthma is a chronic lung disease that inflames and narrows the airways.1 Approximately 2.5 million people in Canada currently have asthma.2 Despite medical advances, more than half of patients continue to experience poor control and significant symptoms.3
The causes of asthma are not completely understood but likely involve an interaction between a person's genetic make-up and the environment. Key risk factors are inhaled substances that provoke allergic reactions or irritate the airways.
GSK – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For information, please visit www.gsk.com.
References
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2013.
- Global Initiative for Asthma. Pocket Guide for asthma management and prevention. Updated 2014.
- Statistics Canada. 2015
- ODPRN Report: Inhaled Corticosteroids (ICS) + Long-Acting Beta Agonists (LABA) in the Treatment of Asthma "Final Consolidated Report" Apr 1st, 2015
SOURCE GlaxoSmithKline Inc.
For further information: GSK enquiries: Canada media inquiries: Media Line, 905 819 3363 (Mississauga); Media Line French, 514 680 4812 (Laval)
Share this article